No connection

Search Results

ASTH vs KMTS

ASTH
Astrana Health, Inc.
BEARISH
Price
$20.33
Market Cap
$1.02B
Sector
Healthcare
AI Confidence
85%
KMTS
Kestra Medical Technologies, Ltd.
BEARISH
Price
$17.87
Market Cap
$1.04B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ASTH
107.0
KMTS
--
Forward P/E
ASTH
9.64
KMTS
-8.35
P/B Ratio
ASTH
1.29
KMTS
3.62
P/S Ratio
ASTH
0.35
KMTS
12.46
EV/EBITDA
ASTH
11.98
KMTS
-5.9

Profitability

Gross Margin
ASTH
10.25%
KMTS
48.75%
Operating Margin
ASTH
3.09%
KMTS
-141.6%
Profit Margin
ASTH
0.33%
KMTS
-172.99%
ROE
ASTH
1.83%
KMTS
-92.65%
ROA
ASTH
2.88%
KMTS
-36.84%

Growth

Revenue Growth
ASTH
99.7%
KMTS
62.7%
Earnings Growth
ASTH
-97.7%
KMTS
--

Financial Health

Debt/Equity
ASTH
1.96
KMTS
0.16
Current Ratio
ASTH
1.4
KMTS
7.32
Quick Ratio
ASTH
1.36
KMTS
7.08

Dividends

Dividend Yield
ASTH
--
KMTS
--
Payout Ratio
ASTH
0.0%
KMTS
0.0%

AI Verdict

ASTH BEARISH

ASTH's Piotroski F-Score of 6/9 indicates a stable but not strong financial foundation, with notable weaknesses in profitability and cash flow generation. The absence of an Altman Z-Score raises concern about default risk, particularly given a high debt/equity ratio of 1.96 and negative earnings growth of -97.7% YoY. While the company exhibits explosive revenue growth (99.7% YoY) and strong earnings surprises in recent quarters, these are not sustainable without improving margins and profitability. The stock trades at a forward P/E of 9.64 but a current P/E of 107.00, suggesting a massive valuation disconnect that reflects overpricing relative to current earnings. The Graham Number of $8.19 and intrinsic value of $1.33 imply severe overvaluation, with the current price of $20.33 trading at a significant premium.

Strengths
Explosive revenue growth of 99.7% YoY
Strong recent earnings surprise history (average +21.43% over last 4 quarters)
Positive recent quarterly EPS growth (Q/Q +15.5%, YoY +103.0%)
Risks
Piotroski F-Score of 6/9 indicates financial stability but not strength, with red flags in profitability and cash flow
Negative earnings growth of -97.7% YoY despite revenue growth, signaling unsustainable business model
Extremely high current P/E of 107.00 vs. forward P/E of 9.64, indicating overvaluation based on current earnings
KMTS BEARISH

KMTS exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9, indicating poor operational health and financial instability. Despite strong top-line revenue growth of 62.7% and a high current ratio of 7.32, the company suffers from deep negative profit margins (-172.99%) and a complete lack of positive earnings. The disconnect between the 'Strong Buy' analyst consensus and the actual technical trend (0/100) and bearish insider selling suggests a significant valuation bubble or over-optimism regarding future scaling.

Strengths
Strong YoY revenue growth of 62.70%
Excellent short-term liquidity (Current Ratio 7.32)
Healthy Gross Margin of 48.75% suggesting product viability
Risks
Critical operational failure indicated by Piotroski F-Score of 1/9
Severe negative profitability (Profit Margin -172.99%)
Strong bearish technical trend with consistent price declines

Compare Another Pair

ASTH vs KMTS: Head-to-Head Comparison

This page compares Astrana Health, Inc. (ASTH) and Kestra Medical Technologies, Ltd. (KMTS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile